Conversely, the use of a V2R antagonist tolvaptan in patients with polycystic kidney disease has been linked to increased total cholesterol and low-density lipoprotein (LDL) levels, suggesting V2R-mediated AVP actions on lipid metabolism [7,50]. Here, AVPR2 is linked to polycystic kidney disease.